{
    "nct_id": "NCT03092453",
    "official_title": "Mature Dendritic Cell Vaccination Against Mutated Antigens in Patients With Advanced Melanoma",
    "inclusion_criteria": "* Histologically confirmed stage III and stage IV M1a/M1b/M1c melanoma. Measurable disease is not required for enrollment eligibility and patients with completely resected disease are permitted.\n* Male or female patients age greater than or equal to 18 years\n* ECOG (Eastern Cooperative Oncology Group) performance status 0-2\n* Required initial laboratory values (performed within 14 days prior to eligibility confirmation by physician-investigator):\n\n  * WBC (white blood cells) >3,000/mm3\n  * Hg (hemoglobin) greater than or equal to 9.0 gm/dl\n  * Platelets >75,000/mm3\n  * Serum Bilirubin < 2.0 mg/dl\n  * Serum Creatinine < 2.0 mg/dl\n* Subjects of reproductive potential must agree to use a medically accepted birth control method during the trial and for at least two months following the trial.\n* Provide written informed consent.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior treatment with more than one line of cytotoxic chemotherapy; prior treatment with one line of cytotoxic chemotherapy is permitted. Prior treatment with targeted therapy (such as ipilimumab, anti-PD1, or BRAF + MEK inhibitor combination) is permitted.\n* Active untreated CNS (central nervous system) metastasis\n* Active infection\n* Prior malignancy (except non-melanoma skin cancer) within 3 years\n* Pregnant or nursing (lactating) women\n* Concurrent treatment with high-dose systemic corticosteroids; local (inhaled or topical) steroids are permitted\n* Known allergy to eggs\n* Prior history of uveitis or autoimmune inflammatory eye disease\n* Known positivity for hepatitis B antibody, hepatitis C antibody, or HIV antibody",
    "miscellaneous_criteria": ""
}